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Abstract
Background: Genital herpes results in considerable morbidity, including risk of neonatal herpes, and is increasingly
being caused by Herpes Simplex Virus (HSV) type 1. Possibly children are less often HSV-1 infected, leaving them
susceptible until sexual debut. We assessed changes in the Dutch HSV-1 and HSV-2 seroprevalence over time and
determinants associated with HSV seropositivity.
Methods: We used data from two population-based seroepidemiological studies conducted in 1995–6 and 2006–7
with a similar study design. Serum samples of 6 months to 44-year-old participants were tested for type-specific
HSV antibodies using HerpesSelect® with a cut-off level of >1.10 for seropositivity. Age and sex-specific HSV-1 and
HSV-2 seroprevalence was weighted for the Dutch population. Logistic regression was performed to investigate
determinants associated with HSV seropositivity.
Results: Overall, weighted HSV-1 seroprevalence was significantly lower in 2006–7 [42.7 % 95 % confidence interval
(CI) 39.9-45.4] than in 1995–6 (47.7 % 95 % CI 44.8-50.7), especially among 10- to 14-year-olds. Overall, weighted
HSV-2 seroprevalence remained stable: 6.8 % in 1995–6 and 6.0 % in 2006–7. Adults who ever had sexual
intercourse were more often seropositive for HSV-1 [adjusted Odds Ratio (aOR) 1.69 95 % CI 1.33-2.16] and HSV-2
(aOR 2.35 95 % CI 1.23-4.52). Age at sexual debut was the only sexual risk determinant associated with HSV-1
seropositivity.
Conclusions: Because of the lower HSV-1 seroprevalence in 2006–7 compared to 1995–6, more adults are
susceptible to genital HSV-1, including women of reproductive age. Given the higher risk of neonatal herpes when
HSV is acquired during pregnancy, prevention and control measures during pregnancy also targeting HSV-1, are
important.
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Background
Herpes Simplex Virus (HSV) can cause orolabial and
genital infections. Most HSV infections are asymptom-
atic, but when symptoms occur, they consist primarily of
ulcerative lesions at the site of infection. HSV infections
remain lifelong and are characterized by latency and
intermitted (sub)clinical reactivity and viral shedding [1].
HSV is highly prevalent with a worldwide estimate of
approximately 3.6 billion people till the age of 49 in-
fected orolabially and half a billion infected genitally [2].
Controlling HSV infections is of public health rele-
vance. When transmitted vertically, HSV can cause neo-
natal herpes. Although occurring rarely (4.7/100,000
livebirths in the Netherlands [3]), neonatal herpes can
have serious consequences such as neurological damage
and death. Other complications of HSV infections in-
clude encephalitis and aseptic meningitis [1]. Moreover,
genital HSV infections are associated with an increased
risk of acquiring and transmitting human immunodefi-
ciency virus (HIV) [4, 5].
There are two types of HSV: HSV-1 and HSV-2. HSV-1
has traditionally been characterized by childhood trans-
mission causing orolabial lesions and HSV-2 by sexual
transmission causing genital herpes. However, the epi-
demiology of HSV is changing and genital herpes is in-
creasingly being caused by HSV-1 in industrialized
countries [6–9]. This leads to HSV-1 being the main cause
of primary genital herpes in some countries [10–12] and
to an important role of HSV-1 in neonatal herpes [3].
A possible explanation for the increasing contribution
of HSV-1 in genital herpes is that children are less often
exposed to HSV-1, leaving them susceptible to genital
HSV-1 [13]. Indeed, different studies observed a decline in
HSV-1 seropositivity among children over time [14, 15].
For prevention and control strategies, it is important
to monitor the epidemiology of HSV infections. In the
Netherlands, a good picture of HSV-1 and HSV-2 in the
general population and changes over time is lacking. By
comparing two large-scale population-based seroepide-
miological studies conducted in 1995–6 and 2006–7, we
investigated changes in age and sex-specific HSV-1 and
HSV-2 seroprevalence in the general Dutch population.
We also investigated determinants associated with HSV-1
and HSV-2 seropositivity, including sexual risk behavior.
Methods
Study design and population
We used data from two cross-sectional population-based
seroepidemiological studies, conducted in the Netherlands
in 1995–6 (Pienter-1) and 2006–7 (Pienter-2). The study
designs were similar and described in detail elsewhere
[16, 17]. Briefly, 40 municipalities equally distributed
over 5 geographical regions were randomly selected
proportional to their population size. An age-stratified
sample was drawn from the population register and in-
vited to donate blood and fill in a questionnaire at
home. In Pienter-2, migrants (people with at least one
parent born abroad) were oversampled. The participa-
tion rates for Pienter-1 and Pienter-2 were 55 % and
32 %, respectively. Pienter-1 was approved by the Med-
ical Ethical Committee of Netherlands Organization for
Applied Scientific Research (TNO) in Leiden. Pienter 2
was approved by the Medical Ethics Testing Committee
of the foundation of therapeutic evaluation of medi-
cines (METC-STEG) in Almere (clinical trial number:
ISRCTN 20164309). All participants gave written in-
formed consent.
We used data from the nationwide sample from all
6 months to 44-year-old participants. Children younger
than 6 months were excluded because of the possible
presence of maternally derived antibodies.
Laboratory methods
Serum samples were stored at −80 °C until analyses (in
2000–1 for Pienter-1 and 2013 for Pienter-2 samples).
Type-specific antibodies were determined with a com-
mercial indirect HSV-1 (gG1) and HSV-2 (gG2) antibody
assay (HerpesSelect®, Focus Technologies, Dypress, CA,
USA) according to the manufacturer instructions [18, 19].
Cut-off levels were >1.10 for seropositivity and <0.90 for
seronegativity. Equivocal samples (1.8 % of all samples for
HSV-1 and 0.6 % for HSV-2) were classified as negative
for all analyses [15, 20].
Statistical analyses
All statistical analyses were corrected for the complex
survey design, by using the Taylor series variance estima-
tion [21]. We calculated the overall and age- and sex-
specific HSV-1 and HSV-2 seroprevalence and their joint
distribution. By assigning sampling weights to each sam-
ple, we calculated the seroprevalence of the general Dutch
population in Pienter-1 and Pienter-2 to study changes
over time. Weights were determined from the Dutch ref-
erence population of 1996 and 2007, taking into account
gender, age, ethnicity and degree of urbanization of the
participants’ residence. Differences in the weighted sero-
prevalence between Pienter-1 and Pienter-2 were calcu-
lated using Chi-square tests.
We performed logistic regression analyses to investi-
gate determinants associated with HSV seropositivity.
Since the rare event assumption was not met, Odds Ra-
tios (OR) cannot be interpreted as relative risks [22].
The logistic regression analyses were unweighted; in-
stead, all logistic regression analyses were adjusted for
the variables that were considered in the weights (gen-
der, age, ethnicity and degree of urbanization) to correct
for oversampling and nonresponse [23].
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Taking into account different risk behavior and possible
different routes of exposure, analyses were performed sep-
arately for children (aged 6 months to 11 years), all adults
(aged 17 to 44 years for Pienter-1 and 15 to 44 years for
Pienter-2, because the questionnaire was distributed to
participants aged 17 or older in Pienter-1 and to partici-
pants aged 15 or older in Pienter-2) and adults who ever
had sexual intercourse. Because there were hardly any dif-
ferences between Pienter-1 and Pienter-2 in determinants
associated with seropositivity (Additional file 1), the stud-
ies were analyzed together.
For HSV-1, we considered as possible determinants:
demographics [gender, age, ethnicity, generation of mi-
grants, degree of urbanization and education level (for
children, the education level of the parents was used)],
social contact variables [number of household members,
child in household attending day care and attending day
care (for children only)] and whether someone ever had
sexual intercourse (for adults only). Among adults who
ever had sexual intercourse, we investigated sexual risk
behavior: number of recent partners (in the past year for
Pienter-1 and 6 months for Pienter-2), sexual preference
based on sexual behavior, self-reported history of specific
sexually transmitted infections (STI), age of sexual debut
and condom use with steady and casual partners in the
past 6 months (Pienter-2 only).
For HSV-2, analyses were performed for adults only,
since children were rarely seropositive. Variables in-
cluded were demographics, whether someone ever had
sexual intercourse and sexual risk behavior (for adults
who ever had sexual intercourse only).
We performed logistic regression analyses separately
for all variables described above adjusted for gender, age,
ethnicity and degree of urbanization. All variables were
included in further multivariable analyses.
Among adults who ever had sexual intercourse, we
calculated the proportion reporting a history of genital
herpes by HSV serostatus, stratified by Pienter study.
These percentages were unweighted in absence of a refer-
ence population by HSV serostatus. Analyses were per-
formed using SAS 9.3 with a significance level of p < 0.05.
Sensitivity analyses
In sensitivity analyses, we repeated the analyses with
equivocal samples classified as positive. In addition, we
performed a sensitivity analysis for the relation between
sexual risk determinants on HSV-1 seropositivity re-
stricted to Native Dutch adults (i.e., excluding migrants),
to increase the proportion of genital HSV-1 infections.
The HSV-1 seroprevalence among migrants in the
Netherlands is very high at a young age [24] probably re-
lated to orolabial infections. Last, we repeated the ana-
lyses for number of sex partners where we converted the
number of partners in the past year (Pienter-1 variable)
to the number of partners in the past 6 months to match
the variable of Pienter-2. We did this by rounding up
the number of partners in the past year divided by 2.
Results
Study population
Sufficient serum was left for 4180 of the 4943 partici-
pants aged 6 months to 44 years in Pienter-1 and for
3757 of the 3928 participants in Pienter-2. Of the 7937
participants included overall, 2887 (36.4 %) were chil-
dren aged 6 months to 11 years and 4276 (53.9 %) were
adults aged 15/17 to 44 years. Of all adults, 3600
(84.2 %) ever had sexual intercourse.
Due to oversampling of migrants in Pienter-2, partici-
pants were less often native Dutch and more often living
in a highly urbanized area in Pienter-2 compared to
Pienter-1. Children in Pienter-2 were less often living
with five or more people, more often living with a child
attending day care and more often attending day care
themselves. Adults in Pienter-2 were more often highly
educated, more often living with a child attending day
care and less often sexually experienced (Table 1).
Weighted seroprevalence
The overall HSV-1 seroprevalence of the general Dutch
population in Pienter-2 was 42.7 % [95 % confidence
interval (CI) 39.9-45.4] and was lower than the overall
seroprevalence of the general population in Pienter-1
(47.7 %, 95 % CI 44.8-50.7, p = 0.01). The weighted HSV-
1 seroprevalence in Pienter-2 was, compared to Pienter-
1, significantly lower among 10- to 14-year-olds and sig-
nificantly higher among 20- to 24-year-old women
(Fig. 1).
The overall HSV-2 seroprevalence of the general Dutch
population in Pienter-2 was 6.0 % (95 % CI 4.8-7.2) and
comparable to the overall seroprevalence of the general
population in Pienter-1 (6.8 %, 95 % CI 5.6-8.0, p = 0.4).
There were some age and sex-specific changes. Among
20- to 24-year-old men and 15- to 19-year-old women,
the weighted HSV-2 seroprevalence was lower in Pienter-
2 compared to Pienter-1 (Fig. 1). The joint distribution of
HSV-1 and HSV-2 seroprevalence in the general popula-
tion is presented in Additional file 2.
Determinants associated with seropositivity
Adjusted for all variables, children in Pienter-2 were less
often HSV-1 seropositive than children in Pienter-1 (ad-
justed OR (aOR) 0.68 95 % CI 0.54-0.85) (Table 2).
Older children, females, children with a non-Western
ethnicity and children with moderately or low educated
parents were more often HSV-1 seropositive. Children
attending day care themselves were also more often
HSV-1 seropositive, while living with children attending
day care was not associated with HSV-1 seropositivity.
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Table 1 Characteristics of the study population (children and adultsa) of Pienter-1 (1995–6) and Pienter-2 (2006–7)
Childrena Adultsa
Pienter-1 Pienter-2 Pienter-1 Pienter-2
N % N % N % N %
Total 1403 1484 2253 2023
Gender
Men 755 53.81 754 50.81 1006 44.65 815 40.29
Women 648 46.19 730 49.19 1247 55.35 1208 59.71
Age (median) 5 5 32 30
Ethnicityb
Native Dutch 1201 85.60 897 60.44 2019 89.61 1689 83.49
Western, other 74 5.27 57 3.84 131 5.81 152 7.51
Moroccan/Turkish 57 4.06 202 13.61 47 2.09 50 2.47
Surinamese/Aruban/Antillean 24 1.71 164 11.05 27 1.20 50 2.47
Non-Western, other 47 3.35 164 11.05 29 1.29 82 4.05
Generation of migrantb
Native Dutch 1201 85.60 897 60.44 2019 89.61 1689 83.49
1st generation 41 2.92 286 19.27 123 5.46 174 8.60
2nd generation 161 11.48 301 20.28 111 4.93 160 7.91
Degree of urbanization
Very high 160 11.40 416 28.03 233 10.34 379 18.73
Less high 1243 88.60 1068 71.97 2020 89.66 1644 81.27
Education levelc
Moderate or low 955 68.07 1014 68.33 1794 79.63 1396 69.01
High 421 30.01 431 29.04 436 19.35 601 29.71
Unknown 27 1.92 39 2.63 23 1.02 26 1.29
Household
1-2 persons 19 1.35 46 3.10 724 32.13 643 31.78
3-4 persons 852 60.73 888 59.84 1086 48.20 1000 49.43
> = 5 persons 520 37.06 515 34.70 408 18.11 356 17.60
Unknown 12 0.86 35 2.36 35 1.55 24 1.19
Child in household attending day care
No 1193 85.03 1154 77.76 1972 87.53 1694 83.74
Yes 184 13.11 278 18.73 237 10.52 295 14.58
Unknown 26 1.85 52 3.50 44 1.95 34 1.68
Child attending day care
No 1091 77.76 1058 71.29 - - - -
Yes 281 20.03 382 25.74 - - - -
Unknown 31 2.21 44 2.96 - - - -
Ever had sexual intercourse
No - - - - 206 9.14 266 13.15
Yes - - - - 1932 85.75 1668 82.45
Unknown - - - - 115 5.10 89 4.40
Numbers and percentages were unweighted
aChildren were aged 6 months to 11 years and adults were aged 17 to 44 years in Pienter-1 and 15 to 44 years in Pienter-2
bIn Pienter-2, migrant populations (people with at least one parent born abroad) were oversampled
cFor children, the education level of the parents was used
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Determinants associated with HSV-1 seropositivity
among adults were comparable to those among children:
being female, being older, having a non-Dutch ethnicity
and being moderately or low educated (Table 2). Adults
who ever had sexual intercourse were more often HSV-1
seropositive than adults who never had sexual inter-
course (aOR 1.69 95 % CI 1.33-2.16).
Participants who were older at sexual debut were less
often HSV-1 seropositive (Table 3). Other sexual risk de-
terminants were not associated with HSV-1 in the multi-
variable analyses. Participants with a self-reported history
of genital herpes had a higher odds of being HSV-1 sero-
positive compared to participants who reported no history
of STI (aOR 1.84), however this was not statistically sig-
nificant (95 % CI 0.75-4.53).
Determinants significantly associated with HSV-2 sero-
positivity among adults were: a female gender; an older
age; a Surinamese, Aruban, Antillean or other non-
Western ethnicity; and a high education level (Table 2).
Sexually experienced adults were more often HSV-2 sero-
positive than adults who never had sexual intercourse
(aOR 2.35 95 % CI 1.23-4.52).
Sexually experienced adults who were homo- or bisex-
ual were more likely to be HSV-2 seropositive compared
to heterosexual adults, however this was not statistically
significant in the multivariable analyses (Table 3). Adults
reporting a history of genital herpes were more often
HSV-2 seropositive than adults reporting no history of
STI (aOR 7.71 95 % CI 3.19-18.60). Condom use in the
past 6 months was not significantly associated with
HSV-2. The results of all sensitivity analyses were com-
parable to the original analyses (Additional files 3, 4, 5).
Genital herpes
Among all HSV-1 seropositive and HSV-2 seronegative
adults who ever had sexual intercourse, 0.8 % reported a
Fig. 1 Weighted seroprevalence of HSV-1 and HSV-2 by gender, age and Pienter study. * Difference in seroprevalence between Pienter-1 and
Pienter-2 is statistically significant (p < 0.05)
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OR [95 % CI]b aOR [95 % CI] OR [95 % CI]b aOR [95 % CI] OR [95 % CI]b aOR [95 % CI]
Pienter
Pienter-1 Ref. Ref. Ref. Ref. Ref. Ref.
Pienter-2 0.69 [0.55-0.86] 0.68 [0.54-0.85] 0.79 [0.66-0.94] 0.80 [0.67-0.96] 0.94 [0.71-1.25] 0.90 [0.68-1.21]
Gender
Men Ref. Ref. Ref. Ref. Ref. Ref.
Women 1.28 [1.09-1.51] 1.32 [1.12-1.56] 1.22 [1.07-1.40] 1.20 [1.04-1.37] 1.46 [1.22-1.74] 1.46 [1.22-1.75]
Age (continuously) 1.21 [1.18-1.23] 1.23 [1.20-1.26] 1.06 [1.05-1.07] 1.05 [1.04-1.06] 1.05 [1.04-1.07] 1.04 [1.03-1.06]
Ethnicity
Native Dutch Ref. Ref. Ref. Ref. Ref. Ref.
Western, other 1.01 [0.64-1.59] 1.03 [0.66-1.62] 1.35 [1.06-1.70] 1.42 [1.12-1.80] 1.23 [0.85-1.78] 1.21 [0.84-1.76]
Moroccan/Turkish 4.02 [2.80-5.78] 4.00 [2.74-5.83] 15.80 [8.15-30.64] 16.30 [8.15-32.61] 0.78 [0.35-1.72] 0.84 [0.37-1.92]
Surinamese/Aruban/Antillean 2.24 [1.67-3.01] 2.55 [1.89-3.43] 2.46 [1.52-4.00] 2.74 [1.69-4.46] 1.85 [1.01-3.37] 2.02 [1.11-3.66]
Non-Western, other 2.45 [1.75-3.42] 2.60 [1.78-3.78] 4.47 [2.65-7.56] 4.79 [2.74-8.37] 1.87 [1.05-3.30] 1.98 [1.12-3.49]
Generation of migrantc
Native Dutch Ref. - Ref. - Ref. -
1st generation 3.29 [2.36-4.57] - 4.84 [3.49-6.70] - 1.59 [1.11-2.28] -
2nd generation 1.94 [1.48-2.53] - 1.38 [1.04-1.83] - 1.05 [0.68-1.62] -
Degree of urbanization
Very high 1.12 [0.85-1.48] 1.16 [0.89-1.50] 0.90 [0.74-1.08] 0.97 [0.81-1.15] 1.07 [0.75-1.52] 1.04 [0.73-1.48]
Less high Ref. Ref. Ref. Ref. Ref. Ref.
Education leveld
Moderate or low 1.43 [1.16-1.77] 1.44 [1.16-1.80] 1.26 [1.07-1.47] 1.23 [1.05-1.45] 0.69 [0.55-0.88] 0.70 [0.55-0.89]
High Ref. Ref. Ref. Ref. Ref. Ref.
Unknown 2.06 [1.19-3.57] 1.53 [0.79-2.98] 1.35 [0.67-2.70] 1.80 [0.85-3.82] 1.10 [0.43-2.85] 1.14 [0.41-3.12]
Household
1-2 persons Ref. Ref. Ref. Ref. - -
3-4 persons 1.58 [0.84-2.95] 1.57 [0.84-2.93] 1.17 [1.02-1.34] 1.14 [0.99-1.31] - -
> = 5 persons 1.64 [0.86-3.13] 1.69 [0.89-3.20] 1.08 [0.89-1.30] 1.10 [0.90-1.34] - -
Unknown 3.94 [2.17-7.16] 3.94 [1.93-8.04] 1.15 [0.65-2.03] 2.04 [1.03-4.04] - -
Child in household attending
day care
No Ref. Ref. Ref. Ref. - -
Yes 0.95 [0.71-1.28] 0.95 [0.71-1.26] 1.17 [0.98-1.41] 1.14 [0.94-1.39] - -
Unknown 1.41 [0.95-2.08] 1.20 [0.58-2.50] 0.48 [0.29-0.78] 0.33 [0.18-0.58] - -
Child attending day care
No Ref. Ref. - - - -
Yes 1.41 [1.07-1.85] 1.50 [1.12-2.01] - - - -
Unknown 1.31 [0.87-1.97] 0.79 [0.36-1.73] - - - -
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history of genital herpes. This increased from 0.5 % in
Pienter-1 to 1.3 % in Pienter-2 (p = 0.06) (Fig. 2). Partici-
pants who were HSV-2 seropositive (irrespective of
HSV-1 serostatus) more often reported a history of geni-
tal herpes (3.8 %).
Discussion
In two population-based studies performed 12 years
apart i.e., 1995–6 and 2006–7, we found that the overall
HSV-1 seroprevalence decreased, while the HSV-2 sero-
prevalence remained stable. Especially among 10- to 14-
year-olds, the HSV-1 seroprevalence was significantly
lower in 2006–7 than in 1995–6. Adults who ever had
sexual intercourse were more likely to be HSV seroposi-
tive, but age at sexual debut was the only sexual risk de-
terminant associated with HSV-1 seropositivity.
There are some limitations. First, we were restricted to
variables available in the Pienter studies. Variables re-
lated to HSV in other studies, like lifetime number of
sex partners and oral sex, were not available and could
therefore not be investigated [15, 25]. Second, the par-
ticipation rate of 55 % in Pienter-1 and 32 % in Pienter-2
could have led to response bias. The participation rate
differed by gender, age and ethnicity in both Pienter
studies and by marital status and degree of urbanization
in Pienter-1 [17, 26]. We tried to minimize possible bias
by correcting for demographic variables by using weights
or by including them as variables in the analyses. Third,
as result of the cross-sectional design, we were unable to
separate age and cohort effects. As HSV-1 and HSV-2
are lifelong infections, it is difficult to infer changes in
seroincidence using seroprevalence in older age groups.
Fourth, according to the manufacturer the specificity of
the HerpesSelect® has increased with 1-2 % since 2000–1
when Pienter-1 samples were tested compared to 2013
when Pienter-2 samples were tested (personal communi-
cation), meaning less false positive samples for Pienter-2
compared to Pienter-1. This could have partially contrib-
uted to the differences between Pienter-1 and Pienter-2.
Last, based on serology it is impossible to make a dis-
tinction between orolabial and genital infections if no
symptoms are reported. We are therefore unable to draw
conclusions about changes in genitally versus non-
genitally acquired HSV-1 infections.
We observed an HSV-1 seroprevalence of 47.7 % in
1995–6 and 42.7 % in 2006–7 among 6 months to 44-
year-olds, which is somewhat lower than the estimated
HSV-1 seroprevalence for the European region (67-69 %)
[2]. However, this European estimate was among 0- to 49-
year-olds and not all countries were included, while there
are large differences between counties, also within Europe.
In a multi-country study, the age standardized HSV-1
seroprevalence of people aged 0 years and older ranged
from 52 % in Finland to 84 % in Bulgaria [20].
The HSV-2 seroprevalence also differs widely between
countries. The age standardized HSV-2 seroprevalence
ranged from 4 % in England and Wales (>14 years old)
to 24 % in Bulgaria (>11 years old) [20]. The HSV-2 sero-
prevalence in the total European region was estimated to
be approximately 7 % among 15- to 49-year-olds [27]. In
our study, the HSV-2 seroprevalence among 15- to 44-
year-olds was 9.1 % in 1995–6 and 8.3 % in 2006–7, which
is slightly higher than the European estimate.
As we hypothesized, we observed a lower HSV-1 sero-
prevalence among children in 2006–7 compared to
1995–6, possibly related to better hygiene. A decline in
HSV-1 seroprevalence among young people was also ob-
served in other countries. In England and Wales, the
HSV-1 seroprevalence among 10- to 14-year-olds de-
clined from 34 % in 1986–7 to 24 % in 1994–5 and in
the US the HSV-1 seroprevalence among 14- to 19-year-
olds declined from 43 % in 1976–80 to 30 % in 2005–10
[14, 15]. The decreased HSV-1 seroprevalence among
children results in an increased age of infection and thus
in higher susceptibility at sexual debut and might partly
explain the increasing importance of HSV-1 in genital
herpes described in the literature [6-9]. The rise in HSV-
1 seroprevalence among 20- to 24-year-old women in
our study could be explained by higher acquisition of
genital HSV-1.
We found no trend in the HSV-2 seroprevalence. This
is also found in the US were the HSV-2 seroprevalence
Table 2 Logistic regression analyses to investigate demographic and social determinants associated with HSV-1 and HSV-2 sero-
positivity (Continued)
Ever had sexual intercourse
No - - Ref. Ref. Ref. Ref.
Yes - - 1.63 [1.29-2.06] 1.69 [1.33-2.16] 2.47 [1.28-4.74] 2.35 [1.23-4.52]
Unknown - - 1.38 [0.98-1.95] 1.39 [0.97-1.99] 2.43 [1.13-5.22] 2.22 [1.03-4.81]
Logistic regression analyses were unweighted, corrected for the complex survey design
In bold: OR is statistically significant (p < 0.05)
HSV herpes simplex virus; OR odds ratio; aOR adjusted odds ratio; CI confidence interval; Ref reference
aChildren were aged 6 months to 11 years and adults were aged 17 – 44 years in Pienter-1 and 15 – 44 years in Pienter-2
bOR adjusted for: gender, age, ethnicity and degree of urbanization
cNot adjusted for ethnicity and not included in multivariable analyses
dFor children, the education level of the parents was used
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among 14- to 49-year-olds was 17 % in 1999–2004 and
16 % in 2005–10 [15]. A study in Finland among preg-
nant women observed a decrease in HSV-2 seropreva-
lence from 18 % in 1992 to 11 % in 2012, but this
decrease was not statistically significant [28].
HSV-1 seropositivity was only slightly associated with
sexual risk behavior in our study. There are several ex-
planations for this. First, perhaps most of the HSV-1
seropositive adults of the general population were in-
fected orolabially instead of genitally. We did repeat the
analyses with native Dutch adults only to increase the
proportion of HSV-1 acquired during adulthood, but this
did not change the results (Additional file 4). Second,
some sexual risk determinants concerned the past 6 or
12 months, while seroconversion could have occurred a
longer time ago. Sexual risk behavior was also only
slightly associated with HSV-2 positivity in our study.
This might explain why others found that condom use
lowered the risk of HSV-2 acquisition [29] and we did
not. Another explanation is that HSV-1 seropositivity is
related to sexual risk behaviors that were not asked in
the Pienter studies, like oral sex [25]. Because informa-
tion about specific sexual practices was not available, we
could not investigate this.
Table 3 Logistic regression analyses to investigate sexual risk determinants associated with HSV-1 and HSV-2 seropositivitya
HSV-1 HSV-2
N (%) OR [95 % CI]b aOR [95 % CI]c OR [95 % CI]b aOR [95 % CI]c
Number of recent partnersd
0 partners 226 (6.28) Ref. Ref. Ref. Ref.
1 partners 3031 (84.19) 1.39 [1.05-1.83] 1.12 [0.71-1.75] 1.28 [0.81-2.04] 0.52 [0.24-1.12]
> = 2 partners 195 (5.42) 1.15 [0.75-1.74] 0.85 [0.50-1.46] 1.51 [0.82-2.78] 0.48 [0.21-1.12]
Unknown 148 (4.11) 1.68 [1.10-2.59] 1.34 [0.84-2.13] 1.27 [0.65-2.48] 0.78 [0.37-1.64]
Sexual preference
Heterosexual 3242 (90.06) Ref. Ref. Ref. Ref.
Homo-/bisexual 47 (1.31) 1.10 [0.66-1.84] 1.23 [0.72-2.11] 2.31 [1.23-4.35] 1.94 [0.98-3.83]
Unknown 311 (8.64) 0.78 [0.62-0.98] 0.87 [0.60-1.26] 0.58 [0.38-0.91] 0.35 [0.17-0.72]
Self-reported history of STI
No 3326 (92.39) Ref. Ref. Ref. Ref.
Yes, excluding genital herpes 123 (3.42) 1.18 [0.79-1.76] 1.18 [0.78-1.76] 1.75 [1.06-2.90] 1.66 [0.98-2.81]
Yes, genital herpes 29 (0.81) 1.88 [0.78-4.50] 1.84 [0.75-4.53] 7.53 [3.20-17.69] 7.71 [3.19-18.60]
Unknown 122 (3.39) 1.11 [0.73-1.68] 1.04 [0.69-1.58] 1.12 [0.60-2.09] 1.21 [0.66-2.22]
Age at sexual debut
<=16 years 871 (24.19) Ref. Ref. Ref. Ref.
17-20 years 1703 (47.31) 0.75 [0.63-0.89] 0.74 [0.62-0.88] 1.20 [0.88-1.63] 1.22 [0.88-1.69]
> = 21 years 562 (15.61) 0.62 [0.51-0.76] 0.64 [0.52-0.78] 1.02 [0.74-1.41] 1.05 [0.74-1.49]
Unknown 464 (12.89) 0.89 [0.72-1.09] 0.85 [0.70-1.04] 0.91 [0.61-1.38] 0.96 [0.63-1.46]
Condom use steady partnere
Consistent 219 (13.13) Ref. - Ref. -
Inconsistent 1068 (64.03) 0.96 [0.70-1.32] - 1.12 [0.65-1.92] -
Unknown/no steady partner 381 (22.84) 0.91 [0.63-1.30] - 0.79 [0.43-1.45] -
Condom use casual partnere
Consistent 80 (4.80) Ref. - Ref. -
Inconsistent 68 (4.08) 1.25 [0.67-2.32] - 0.30 [0.07-1.25] -
Unknown/no casual partner 1520 (91.13) 1.04 [0.66-1.63] - 0.62 [0.31-1.24] -
Numbers and percentages were unweighted. Logistic regression analyses were unweighted, corrected for the complex survey design
In bold: OR is statistically significant (p < 0.05)
HSV herpes simplex virus; OR odds ratio; aOR adjusted odds ratio; CI confidence interval; Ref reference; STI sexually transmitted infection
aOnly adults who ever had sexual intercourse were included. Adults were aged 17 to 44 years in Pienter-1 and 15 to 44 years in Pienter-2
bOR adjusted for: gender, age, ethnicity and degree of urbanization
cAdjusted for all variables including those presented in Table 2
dNumber of partners in the past year for Pienter-1 and in the past 6 months for Pienter-2
eCondom use in the past 6 months. Available for Pienter-2 only
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Comparable with other research, we observed that
HSV-1 seropositivity was associated with younger age at
sexual debut and that participants who ever had sexual
intercourse were more likely to be HSV seropositive, in-
dicating sexual transmission [25, 30, 31].
In addition to the limited association between sexual
risk behavior and HSV-1 seropositivity, only 0.8 % of the
HSV-1 seropositive and HSV-2 seronegative sexually ex-
perienced adults reported a history of genital herpes.
This percentage increased from 0.5 % in Pienter-1 to
1.3 % in Pienter-2. In comparison, the proportion of
HSV-2 seropositive adults who reported a history of
genital herpes was higher (3.8 %), but not as high as re-
ported in literature, for example 14 % in the US and 6 %
in Canada [32, 33], perhaps due to missing data. Among
all adults who ever had sex 3 % did not respond to the
STI history question while among HSV-2 seropositive
adults this was 6 %. If people with a history of genital
herpes were less likely to respond, we underestimated
genital herpes.
Other than sexual risk behavior, HSV-1 seropositivity
was associated with female gender, being older, non-
Dutch ethnicity and low education level, which is com-
parable to other settings [24, 25, 31]. Children attending
day care were more likely to be HSV-1 seropositive than
children not attending day care. Interestingly, while the
proportion of children attending day care increased over
time, the HSV-1 seroprevalence decreased.
Females, older participants and participants with a
Surinamese, Aruban, Antillean or other non-Western
ethnicity were more often HSV-2 seropositive, which is
comparable with the literature [20, 32]. In contrast to
the majority of the literature, in our study, low or mod-
erately educated participants were less likely to be HSV-
2 seropositive [24, 32]. A few other studies also reported
that low educated people or people living in low socio-
economic status areas were less often HSV-2 seroposi-
tive [34, 35]. The exact mechanism for this is unclear.
The reduced HSV-1 seroprevalence has several impli-
cations. First, since a previous HSV-1 infection decreases
the likelihood of symptomatic HSV-2 infections, the re-
duced HSV-1 seroprevalence will lead to more symp-
tomatic HSV-2 infections, assuming it will have no or
little influence on the rate of HSV-2 infections [36]. Sec-
ond, a higher HSV-1 susceptible population leads to
more genital acquisition of HSV-1, which in the third
trimester of pregnancy leads to a higher risk of neonatal
herpes [1]. Although still low, the incidence of neonatal
herpes in the Netherlands has increased [3]. More at-
tention can be paid to the HSV serostatus (including
HSV-1) of pregnant women and their partners. For ser-
odiscordant couples the risk of acquiring HSV during
Fig. 2 Proportion of adults reporting a history of genital herpes by HSV serostatus and Pienter study. Only adults who ever had sexual intercourse
were included. Proportions are unweighted
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pregnancy and possible preventive measures, like anti-
viral treatment of the infected partner and abstinence
of unprotected (oral) sex, can be discussed. Vaccines to
prevent HSV are being developed, however to date, vac-
cine research has focused primarily on HSV-2 and has
not been very successful in preventing transmission
thus far [37]. To prevent genital and neonatal herpes,
vaccines must target both HSV-1 and HSV-2.
Conclusions
Since HSV-1 seroprevalence has decreased, more adults
are susceptible to genital HSV-1, including women of re-
productive age. It is important to keep monitoring the de-
velopment of HSV-1 and HSV-2 infections and associated
diseases in the population, specifically for the risk of neo-
natal herpes, vaccine program management and adequate
communication to professionals and public. This can be
achieved by measuring HSV in the upcoming Pienter-3
seroepidemiological study as well.
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